- According to the primary investigator, “significant and clinically meaningful improvements” were demonstrated for the addition of tafasitamab (Tafa) to lenalidomide (LEN) by comparing patients from 2 different trials.
Why this matters
- Patients with relapsed/refractory (R/R) diffuse large B-cell lymphomas (DLBCL) who are ineligible for transplantation have a poor prognosis and few treatment options.
- Tafa is an anti-CD19 antibody with direct tumor cytotoxicity in clinical trials for DLBCL.
- RE-MIND is a global real-world data study of LEN in DLBLC. L-MIND is an ongoing, open-label, phase 2 study of Tafa+LEN. L-MIND provided a matched cohort to RE-MIND with the goal of isolating the contribution of Tafa to combination therapy.
- 76 patients from each trial were matched for 9 baseline characteristics through electronic case records.
- Median follow-up was approximately 21 months.
- Funding: MorphoSys AG.
- The primary outcome of a significantly better overall response rate (ORR) under Tafa was met: 67.1% vs 34.2%. The odd ratio of ORR was 3.9 (95% CI, 1.9-8.1; P<.0001>
- Complete responses: 39.5% vs 13.2%.
- Median progression-free survival: 12.1 vs 4.0 months.
- Median overall survival: not reached vs 9.4 months.
- Unusual, indirect comparison of 2 different drug regimens across different trials.